Design of structure-based reverse transcriptase inhibitors.
نویسندگان
چکیده
منابع مشابه
Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
A computer model of reverse transcriptase (RT) from human immunodeficiency virus type 1 (HIV-1) was used to design thiourea compounds that were predicted to inhibit RT. The RT model was used to approximate how changes in binding pocket shape, volume and chemical properties resulting from residue mutations would affect inhibitor binding. Our lead compound, N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-...
متن کاملNucleotide Reverse Transcriptase Inhibitors
4 Optimal HIV-1 suppression often is difficult to achieve and maintain with currently available antiretroviral drugs, and viral resistance eventually emerges to many drugs. Chronic antiretroviral therapy is also associated with complications such as body fat redistribution, hypertriglyceridemia and hypercholesterolemia, abnormal glucose metabolism, lactic acidosis, pancreatitis, avascular necro...
متن کاملNucleoside Reverse Transcriptase Inhibitors
Although the incidence of HIV infection among women is increasing, the proportion of women in clinical trials that evaluate interventions for the treatment of HIV infection and its complications has historically been lower than the proportion of women in the HIV/AIDS patient population. Therefore, most knowledge about the efficacy of antiretroviral drugs and the adverse reactions associated wit...
متن کاملDenovo insilico design of triazole analogs as reverse transcriptase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have, in addition to the nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), gained a definitive place in the treatment of HIV-1 infections. The present work deals with computational ligand docking methodology, AutoDock 4.0, based on Lamarckian genetic algorithm for virtual screens of a compound database of ...
متن کاملHIV Nucleoside Reverse Transcriptase Inhibitors
Currently, 16 antiretroviral drugs are approved for treatment of HIV infection. However, even the best currently available regimens pose challenges with regard to adherence, toxicity, antiviral activity, and resistance. New drug development thus confronts the need for improved convenience and tolerability, reduced toxicity, and improved activity against both wild-type and drug-resistant viruses...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Biological Chemistry
سال: 1994
ISSN: 0021-9258
DOI: 10.1016/s0021-9258(17)32676-5